These data suggest that, as DCA is a small molecule able to traverse the blood-brain-barrier, further research into its mechanism of action with respect to APP proteolysis may lead to the development of therapies for slowing the progression of Alzheimer’s disease. The gene discussed is APP; the disease is Alzheimer disease.